Obesity Drug M&A Speculation Rises Following Vertex's $10 Billion Deal

Key Facts

1Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals in a deal valued at $10 billion.

2Viking Therapeutics is speculated as the next takeover target due to its promising obesity drug VK2735.

Amid the rapid expansion of the global obesity treatment market, investors are pivoting toward a new wave of strategic acquisitions in the biotech sector. Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals in a deal valued at $10 billion. This move reinforces expectations that major pharmaceutical players are aggressively seeking advanced drug platforms to secure a foothold in the high-growth weight-loss market.

Speculation is mounting that Viking Therapeutics could be the next takeover target due to its promising obesity drug VK2735, as the sector is projected to reach $190 billion by 2035. Per market data, VRTX closed at $483.33 (close July 29, 2026), while VKTX stood at $33.86 (close July 28, 2026). This M&A activity highlights the trend of big pharma acquiring biotech firms with late-stage clinical assets to drive future growth.

Traders should monitor VKTX price levels, which saw a day low of $32.72 on July 28, 2026, as the market awaits critical Phase 3 data that could catalyze a formal bid. In the absence of immediate sector-specific economic calendar events, stock valuations will likely remain sensitive to clinical trial updates and further consolidation rumors in the pharmaceutical space.